D. Keith Grossman
Keith has been a leader in the medical technology industry for more than 30 years. He is currently the President and CEO of Nevro Corporation (NVRO). Prior to Nevro, he was named President and CEO of Thoratec Corp (THOR) for the second time in 2014. Keith led the company’s return to growth, a 2.5x increase in company value and its $3.4 billion acquisition by St. Jude Medical in 2015. He previously served as the CEO, President and Director of Conceptus, Inc. (CPTS) from 2011 to 2013, where he took the company from negative sales growth to over 20% growth, tripled EBIDTA, and led the company’s sale to Bayer Healthcare for over $1.1 billion, a 3x increase in the company’s value prior to his arrival. From 2007 to 2011, Keith served as Managing Director for TPG Biotech, the $1.1 billion venture capital arm of the private equity firm Texas Pacific Group (TPG). Prior to TPG, he served as CEO, President and Director of Thoratec Corporation from 1996 to 2006, increasing the company’s market value more than 12x, and leading the company from no revenue to more than $200 million in annual revenues. Prior to Thoratec, Keith held a number of commercial and general management roles with companies including SulzerMedica and American Hospital Supply Corp. Keith serves as a Director of ViewRay, Inc., Vyaire Medical and TherOx, Inc., and he is a former member of the Board of Directors of Intuitive Surgical, Inc. (ISRG), Kyphon, Inc. (KYPH), Zeltiq (which was acquired by Allergan in 2017), and a number of private medical technology companies.
Chief Executive Officer
Leslie joined Outset from Warburg Pincus where she was an Executive in Residence. Previously, she was Executive Vice President at Lutonix, a cardiovascular medical device company acquired by CR Bard. Prior to Lutonix, Leslie served as Chief Business Officer of AccessClosure, a vascular closure company acquired by Cardinal Health. Before joining AccessClosure, she was the Vice President, Marketing for FoxHollow Technologies, helping to architect the strategy and commercial infrastructure that led to a successful IPO and subsequent acquisition by ev3/Covidien. Leslie’s management experience also includes senior leadership positions at Cytyc Corporation and breast cancer diagnostics company Pro-Duct Health, Inc., which was acquired by Cytyc. She began her medical device career at Guidant Corporation. Leslie received her undergraduate degree from Northwestern University and her MBA from the Haas School of Business, UC Berkeley.
Scott has more than 25 years’ experience as a healthcare executive and director. Scott is currently a Director for Alliance HealthCare Services, Inc., Cardiovascular Systems Inc. and Outset Medical. He previously served as Chairman & CEO for Rural/ Metro Corporation, the nation’s leading provider of ambulance, fire protection and safety services. Rural/Metro was sold in October of 2015. Prior to that, Scott was President, Chief Executive Officer, and Director of LaVie Care Centers, a national long-term care company with revenues exceeding $1 billion annually, from July 2009 through the sale of the company in December 2011. From December 2008 to July 2009, he was an Executive in Residence at Warburg Pincus LLC. Scott was Division President for Gambro Healthcare, Inc. from 2000 to 2004 and COO-East from 2004 to 2005. Scott previously was the founder, President, CEO and a Director of Endoscopy Specialists Inc. He has extensive experience in business design, strategic planning, new product and service innovation, sales and marketing, and mergers and acquisitions with large, medium and small businesses in both public and private companies.
In Seon Hwang
In Seon is based in New York, joined Warburg Pincus in 2004 and leads the firm’s investment activities in the healthcare, consumer and retail sectors. In Seon is also a member of the firm’s Executive Management Group. Previously, he worked at GSC Partners, Goldman Sachs and the Boston Consulting Group. In Seon currently serves as a director of Glansaol, Outset Medical, Silk Road Medical and Specialists on Call. In Seon also serves on the External Advisory Board of the Institute for Translational Medicine and Therapeutics at the School of Medicine of the University of Pennsylvania and on the board of Hope for New York. In Seon received a B.S. in economics from the Wharton School of the University of Pennsylvania and an M.B.A. from Harvard Business School.
Camilla Macapili Languille
Camilla is based in Abu Dhabi, UAE, joined Mubadala Investment Company in 2013, and leads the firm’s investment activities in Pharma & Medtech globally. She has worked across multiple industries within the corporate finance and principal investment fields in North America, Europe and MENA, with a focus on healthcare and industrials. Prior to Mubadala, Camilla worked in M&A and investments for Daiwa Capital and Société Générale based in Paris, and in investments for Virgin Group’s headquarters in London, where she managed the Special Situations portfolio, served as Board Director and/or Chairwoman for several companies, and helped to launch Virgin Healthcare. She began her career in Healthcare M&A for JPMorgan in New York and London, focusing on pharma and biotech. Camilla received a B.A. summa cum laude in Economics & Political Science from Columbia University. She has lived in 14 countries across 4 continents and speaks several languages.
Annette is based in New York, joined Warburg Pincus in 2008, and focuses on investments in the healthcare and consumer sectors. Annette works closely with and serves on the boards of TriMark, the #1 distributor of foodservice equipment and supplies in North America, Outset Medical, a pioneering medical technology company and Glansaol, a global beauty and personal care company. She was involved in the firm’s former investments in Neiman Marcus and Scotsman Industries. Prior to joining Warburg Pincus, Annette worked at JPMorgan Partners (nka CCMP Capital), the private equity arm of J.P. Morgan, as a Generalist. She received a B.S. magna cum laude in economics with concentrations in finance and accounting from the Wharton School at the University of Pennsylvania and an M.B.A. with distinction from Harvard Business School.
Rohit Vishnoi, Ph.D.
Rohit serves as the Corporate Vice President for the Global Device R&D organization at Hospira where he is responsible for providing strategic and operational direction. In addition, he serves on advisory boards for the Biomedical Engineering departments of Northwestern University and University of Illinois at Chicago. Prior to joining Hospira, Rohit was the Vice President for Global Product Development for the Renal Division at Baxter Healthcare. Over a 20-year career at Baxter, he held positions of increasing responsibility in R&D and general management. Teams he led were the recipients of the Janus de la Santé Award in 2006, the Medical Design Excellence Award in 2005, and the R&D 100 Award for technologically significant product development in 1995. Rohit received his Masters of Management in Marketing and Finance in 1995 from Northwestern University and his Ph.D. in 1988 from the Rensselaer Polytechnic Institute. He received his Bachelor of Technology in Electrical Engineering from the Indian Institute of Technology, Kanpur in 1982. As an inventor, Rohit has been granted eleven design patents.